Journal article
Turning the Tide on Hepatitis C Virus–Related Liver Transplantation: The Return on Investment in Hepatitis C Virus Treatment in Australia and New Zealand
J Howell, A Majumdar, MA Fink, M Byrne, G McCaughan, SI Strasser, M Crawford, P Hodgkinson, KA Stuart, C Tallis, J Chen, A Wigg, R Jones, B Jaques, G Jeffrey, L Adams, MC Wallace, S Munn, E Gane, AJ Thompson Show all
Liver Transplantation | Published : 2022
DOI: 10.1002/lt.26329
Abstract
Introduction of universal access to direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) in Australia and New Zealand on March 1st, 2016, has had a major impact on the number of people with chronic HCV infection, but the impact on liver transplantation rates is unknown. We conducted a retrospective registry study including all adult liver transplantations from the Australia and New Zealand Liver and Intestinal Liver Transplant Registry (ANZLITR) data set. Interrupted time series analysis determined the impact of DAAs in 2016 on the number of HCV liver transplantations per year. Cox regression analysis was used to determine the impact of DAAs on post–liver transplantation surviva..
View full abstract